From Data to Discovery: How Abu Dhabi Is Building a Global-Scale Smart Health Ecosystem

As health systems worldwide wrestle with rising costs, fragmented data, and sluggish innovation pipelines, Abu Dhabi is quietly assembling something different: a healthcare ecosystem designed to predict, prevent, and personalize care at scale. At the core of this transformation is an unprecedented convergence of genomics, clinical data, AI infrastructure, and global collaboration — not just for the UAE’s population, but as a platform the world can plug into.

Speaking on behalf of the Department of Health Abu Dhabi (DoH), a representative — under the leadership of Dr. Asma Al Mannaei, Executive Director of the Health Life Sciences Sector — shared the strategic backbone of this transformation and how the emirate is positioning itself as a living laboratory for the future of healthcare.

A Genomic Dataset as Diverse as the World

“In 2019, we launched the Emirati Genome Program with the goal of sequencing one million genomes,” the DoH representative explained. “As of now, we’ve sequenced over 830,000.” That makes it one of the largest and most inclusive genomic initiatives in the world.

Why inclusive? Because Abu Dhabi’s population spans more than 220 nationalities — creating a real-world dataset that reflects global genetic diversity. This, according to the Department, opens up possibilities that go far beyond local impact.

“Most pharmacogenomics data is based on North American or European populations,” they noted. “But by analyzing the genetic makeup of our residents, we can determine which medications are truly effective for them — reducing side effects, improving recovery, and ultimately redesigning how care is delivered.”

For industry players, the implications are significant. Drug developers and diagnostics companies often struggle with underrepresentation in clinical data, which can result in therapies that underperform in non-Western populations. Accessing a large, high-quality and ethnically diverse genomic database — linked to clinical and lifestyle data — creates a real-world testbed for developing and validating treatments with global relevance.

“This is a resource that can de-risk R&D and improve translational accuracy,” the Department said. “It’s not just data — it’s an opportunity to design more equitable, effective therapies from day one.”

Genomics in Action: From Marriage to Oncology

So how does this translate to real-world patient outcomes?

• Pharmacogenomics reports tailored to local populations have already improved medication efficacy.
• Premarital genetic screening helps reduce hereditary disease risks — a sensitive but crucial initiative in regions where consanguineous marriages are common.
• Precision oncology programs at Cleveland Clinic Abu Dhabi now guide treatment based on genetic risk, while lifestyle interventions aim to prevent disease in high-risk groups.

“All of this reflects our goal: to create a smart system that’s not just treating illness, but preventing it before it starts.”

One File, One System, Full Access

Genomics is only one part of the puzzle. Abu Dhabi’s next major investment: a fully integrated clinical data platform known as MALAFFI (Arabic for “my file”). It’s more than a medical record system — it’s a national health information exchange that connects 100% of healthcare providers across the emirate.

“With over 3 billion episodes of clinical data, every one of Abu Dhabi’s 4.1 million residents has a unified medical file,” the DoH representative said. “Physicians — more than 52,000 of them — can access everything from imaging to prescriptions to vaccination history. And in emergencies, this real-time access can save lives.”

But for stakeholders beyond the UAE, MALAFFI also represents something rare: a centralized, consent-based, longitudinal dataset covering a full population in a digitally mature health system. It provides a live, system-wide view of patient journeys — ideal for testing digital health solutions, validating AI models, and conducting real-world evidence (RWE) studies.

“There’s a global shortage of environments where new digital tools can be tested on real data, at scale, with regulatory support,” the Department noted. “What MALAFFI offers is a unique chance to pilot innovations in an ecosystem where the data is integrated, the infrastructure is ready, and the patient benefits are measurable.”

For digital therapeutics developers, AI-enabled diagnostics companies, and clinical trial networks, the opportunities include:

• Deploying and refining algorithms in live clinical settings
• Linking interventions to outcomes across systems and specialties
• Accelerating R&D through anonymized, high-quality datasets
• Collaborating with regulators to develop safer, faster digital health approvals

In short, MALAFFI is not only a national backbone for better care — it’s a platform where the next generation of health technologies can be co-developed and proven in real-world conditions.

Layering in Lifestyle: A 360° View of Health

The next frontier: collecting lifestyle data — sleep, exercise, nutrition, mental health — and integrating it with clinical and genetic data. “When you combine these layers, you get a comprehensive view of population health,” the Department said. “But the challenge becomes making sense of it all. That’s where AI comes in.”

AI, Everywhere: From Hospitals to the Home—Predicting Outbreaks, Preventing Crises

The DoH has developed an AI-enabled vision of care across four levels: individuals, physicians, providers, and policymakers. “We want a system that can predict, prevent, and act — not just react,” they emphasized.

• For individuals, the “Sahatna” app (“Our Health” in Arabic) empowers users to access their own clinical and lifestyle data — and soon, genomics. “It gives people actionable recommendations: Do I need to see a doctor? Should I adjust my diet? It’s like talking to your health data.”
  
• For physicians, a proprietary large language model, Med42, is being deployed. “Doctors can now chat with the entire clinical dataset in Malaffi. It saves time, improves decisions, and streamlines care.”
  
• At the provider level, AI is used in medical imaging and hospital resource allocation. “We’re already using AI to detect disease faster — but also to route patients to the right place at the right time during emergencies.”
  
• At the system level, Abu Dhabi has built a digital twin of its population for policy testing. “Before we roll out a new diabetes policy, we simulate its impact on cost, care, and health outcomes. It’s policymaking with foresight.”

This AI-first model has already proved its worth. “In 2024, our models flagged a potential measles outbreak,” the representative recalled. “We vaccinated 89,000 people proactively. Months later, outbreaks hit the U.S., U.K., and Morocco — but we were prepared.”

This response is coordinated by Abu Dhabi’s Unified Medical Operations Center, which manages real-time emergency responses — from hospital capacity to supply chain optimization — all using AI.

Building an End-to-End Life Sciences Cluster

All this infrastructure serves a broader vision: turning Abu Dhabi into a full-cycle life sciences hub — from R&D to manufacturing to global distribution.

• M42, the AI-driven healthcare provider behind Cleveland Clinic Abu Dhabi and Imperial College London Diabetes Centre, is integrating robotics and AI into its core operations.
• Mubadala Bio, a new investment vehicle, is funding biotech innovations.
• ADIO (Abu Dhabi Investment Office) offers co-investment programs, tax incentives, and partnerships for companies setting up in the UAE.
• SaaS Zones near airports and seaports are optimized for biomanufacturing and rapid export.

“Once you develop a therapy or product here, you can manufacture it, get regulatory support, and distribute it globally — all within the ecosystem,” said the Department.

A Living Lab for Global Health Innovation

Abu Dhabi isn’t just building infrastructure — it’s inviting the world to use it.

At the heart of its life sciences strategy is a commitment to collaborative innovation. More than 90 biotech and health tech startups are already active in Masdar City, leveraging shared lab facilities and testing solutions in clinical environments like M42 and Pure Health — the UAE’s largest healthcare group, now with international operations in the UK and Greece. From early-stage prototyping to clinical validation, the emirate offers a full pipeline from ideation to commercialization.

“For innovators, this isn’t just about acceleration — it’s about access,” said the Department.  “Access to data, infrastructure, clinicians, and regulators in one integrated environment.”

But the message to the global health community is clear: Abu Dhabi can’t — and won’t — do it alone. Through events like Abu Dhabi Global Health Week, which drew over 15,000 international participants, and US BIO the emirate is positioning itself as a platform for shared progress on issues like longevity, AI ethics, and precision medicine.

For industry players, the opportunity is twofold:

• Test and refine innovations in a real-world, system-wide environment
• Co-create scalable solutions with support from regulators, investors, and providers

Whether you’re a startup, a pharmaceutical company, or a digital health platform, Abu Dhabi offers a rare chance to plug into a connected ecosystem — one that is not only ready to adopt, but also help shape, the future of global health. As the Department puts it: “Test here. Build here. Scale globally.”

Startups Welcome: Testing Ideas in a Real-World Lab, A Call for Global Collaboration

“Our goal is to support innovators from idea to commercialization — to give them access to infrastructure, data, and clinical partners,” said the DoH. “We’re not just accelerating products. We’re accelerating impact.” Abu Dhabi may have the infrastructure, but it knows it can’t go it alone.

“We’re calling on researchers, innovators, and investors from around the world to come test their ideas in Abu Dhabi — and scale globally,” said the representative. “Think of it as a living lab. The data, the compute power, the partners — it’s all here. We just need the right collaborations.”

That vision took center stage at Abu Dhabi Global Health Week, now in its second year. With over 15,000 attendees, including leaders from GSK and AstraZeneca, the event focuses on longevity, precision medicine, and the ethical use of AI. “It’s about connecting and solving problems that no single country can tackle alone.”

In an era of exponential medical data and escalating health demands, Abu Dhabi’s system offers something rare: a way to act smarter, earlier, and at scale. But what makes it truly different is its invitation — not to watch, but to participate.

“Test here. Build here. Scale globally,” the Department urges. “Let’s solve tomorrow’s health challenges — together.”

GeneOnline CEO Thomas Huang (left) spoke with the Department of Health Abu Dhabi representative (right) at BIO US in Boston, discussing how Abu Dhabi’s integrated ecosystem — from its Emirati Genome Program to the AI-driven MALAFFI platform — is redefining global health innovation through real-world data access, regulatory collaboration, and end-to-end support for biotech development. Image: GeneOnline.

Author

Bernice Lottering